{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:01:59Z","timestamp":1790402519693,"version":"4.1.0"},"reference-count":98,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Duchenne muscular dystrophy (DMD) is a severe X-linked disorder characterized by progressive muscle degeneration due to mutations in the dystrophin gene. Despite major advancements in understanding its pathophysiology, there is still no curative treatment. This review provides an up-to-date overview of current and emerging therapeutic approaches\u2014including antisense oligonucleotides, gene therapy, gene editing, corticosteroids, and histone deacetylases(HDAC) inhibitors\u2014aimed at restoring dystrophin expression or mitigating disease progression. Special emphasis is placed on the importance of early diagnosis, the utility of genetic screening, and the innovations in pre-and post-natal testing. As the field advances toward personalized medicine, the integration of precision therapies with cutting-edge diagnostic technologies promises to improve both prognosis and quality of life for individuals with DMD.<\/jats:p>","DOI":"10.3390\/ijms26146742","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T09:45:52Z","timestamp":1752572752000},"page":"6742","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Duchenne Muscular Dystrophy: Integrating Current Clinical Practice with Future Therapeutic and Diagnostic Horizons"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9309-1666","authenticated-orcid":false,"given":"Costanza","family":"Montagna","sequence":"first","affiliation":[{"name":"Departmental Faculty of Medicine, UniCamillus\u2014Saint Camillus International University of Health and Medical Sciences, 00131 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiliano","family":"Maiani","sequence":"additional","affiliation":[{"name":"Departmental Faculty of Medicine, UniCamillus\u2014Saint Camillus International University of Health and Medical Sciences, 00131 Rome, Italy"},{"name":"IRCCS San Camillo Hospital, 30126 Venice, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7141-1817","authenticated-orcid":false,"given":"Luisa","family":"Pieroni","sequence":"additional","affiliation":[{"name":"Departmental Faculty of Medicine, UniCamillus\u2014Saint Camillus International University of Health and Medical Sciences, 00131 Rome, Italy"},{"name":"IRCCS San Camillo Hospital, 30126 Venice, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8640-8212","authenticated-orcid":false,"given":"Silvia","family":"Consalvi","sequence":"additional","affiliation":[{"name":"Departmental Faculty of Medicine, UniCamillus\u2014Saint Camillus International University of Health and Medical Sciences, 00131 Rome, Italy"},{"name":"IRCCS San Camillo Hospital, 30126 Venice, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1016\/S0140-6736(19)32910-1","article-title":"Muscular Dystrophies","volume":"394","author":"Mercuri","year":"2019","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne Muscular Dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10654-020-00613-8","article-title":"Life expectancy at birth in Duchenne muscular dystrophy: A systematic review and meta-analysis","volume":"35","author":"Landfeldt","year":"2020","journal-title":"Eur. J. Epidemiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.nmd.2014.03.008","article-title":"A Systematic Review and Meta-Analysis on the Epidemiology of Duchenne and Becker Muscular Dystrophy","volume":"24","author":"Mah","year":"2014","journal-title":"Neuromuscul. Disord."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/j.2040-4603.2015.tb00638.x","article-title":"The Dystrophin Complex: Structure, Function, and Implications for Therapy","volume":"5","author":"Gao","year":"2015","journal-title":"Compr. Physiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0074-7696(07)65005-0","article-title":"Biology of the Striated Muscle Dystrophin-Glycoprotein Complex","volume":"265","author":"Ervasti","year":"2008","journal-title":"Int. Rev. Cytol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.bbamem.2013.08.023","article-title":"Dystrophin Complex Functions as a Scaffold for Signalling Proteins","volume":"1838","author":"Constantin","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1152\/physrev.00007.2015","article-title":"Absence of Dystrophin Disrupts Skeletal Muscle Signaling: Roles of Ca2+, Reactive Oxygen Species, and Nitric Oxide in the Development of Muscular Dystrophy","volume":"96","author":"Allen","year":"2016","journal-title":"Physiol. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1212\/WNL.25.12.1111","article-title":"Duchenne Dystrophy: Electron Microscopic Findings Pointing to a Basic or Early Abnormality in the Plasma Membrane of the Muscle Fiber","volume":"25","author":"Mokri","year":"1975","journal-title":"Neurology"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Dubinin, M.V., and Belosludtsev, K.N. (2023). Ion Channels of the Sarcolemma and Intracellular Organelles in Duchenne Muscular Dystrophy: A Role in the Dysregulation of Ion Homeostasis and a Possible Target for Therapy. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032229"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"13818","DOI":"10.1073\/pnas.250379497","article-title":"Functional muscle ischemia in neuronal nitric oxide synthase-deficient skeletal muscle of children with Duchenne muscular dystrophy","volume":"97","author":"Sander","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10974-012-9330-9","article-title":"Contribution of Oxidative Stress to Pathology in Diaphragm and Limb Muscles with Duchenne Muscular Dystrophy","volume":"34","author":"Kim","year":"2013","journal-title":"J. Muscle Res. Cell Motil."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5325","DOI":"10.1242\/jcs.114041","article-title":"Misregulation of Autophagy and Protein Degradation Systems in Myopathies and Muscular Dystrophies","volume":"126","author":"Sandri","year":"2013","journal-title":"J. Cell Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"299rv4","DOI":"10.1126\/scitranslmed.aaa7322","article-title":"Immune-Mediated Pathology in Duchenne Muscular Dystrophy","volume":"7","author":"Rosenberg","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1038\/nm.3990","article-title":"Dystrophin Expression in Muscle Stem Cells Regulates Their Polarity and Asymmetric Division","volume":"21","author":"Dumont","year":"2015","journal-title":"Nat. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.nmd.2007.03.002","article-title":"Managing Duchenne Muscular Dystrophy\u2014The Additive Effect of Spinal Surgery and Home Nocturnal Ventilation in Improving Survival","volume":"17","author":"Eagle","year":"2007","journal-title":"Neuromuscul. Disord."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1080\/14740338.2024.2394578","article-title":"Corticosteroids for the Treatment of Duchenne Muscular Dystrophy: A Safety Review","volume":"23","author":"Czifrus","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","article-title":"Long-Term Effects of Glucocorticoids on Function, Quality of Life, and Survival in Patients with Duchenne Muscular Dystrophy: A Prospective Cohort Study","volume":"391","author":"McDonald","year":"2018","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/mus.26736","article-title":"Deflazacort vs Prednisone Treatment for Duchenne Muscular Dystrophy: A Meta-Analysis of Disease Progression Rates in Recent Multicenter Clinical Trials","volume":"61","author":"McDonald","year":"2020","journal-title":"Muscle Nerve"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1001\/jamaneurol.2022.2480","article-title":"Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial","volume":"79","author":"Guglieri","year":"2022","journal-title":"JAMA Neurol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e208112","DOI":"10.1212\/WNL.0000000000208112","article-title":"Efficacy and Safety of Vamorolone over 48 Weeks in Boys with Duchenne Muscular Dystrophy: A Randomized Controlled Trial","volume":"102","author":"Dang","year":"2024","journal-title":"Neurology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40265-023-01986-2","article-title":"Vamorolone: First Approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/mus.24332","article-title":"Ataluren Treatment of Patients with Nonsense Mutation Dystrophinopathy","volume":"50","author":"Bushby","year":"2014","journal-title":"Muscle Nerve"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","article-title":"Ataluren in Patients with Nonsense Mutation Duchenne Muscular Dystrophy (ACT DMD): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"390","author":"McDonald","year":"2017","journal-title":"Lancet"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.nmd.2014.11.011","article-title":"European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene","volume":"25","author":"Haas","year":"2015","journal-title":"Neuromuscul. Disord."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1007\/s00415-023-11687-1","article-title":"Safety and Effectiveness of Ataluren in Patients with Nonsense Mutation DMD in the STRIDE Registry Compared with the CINRG Duchenne Natural History Study (2015\u20132022): 2022 Interim Analysis","volume":"270","author":"Mercuri","year":"2023","journal-title":"J. Neurol."},{"key":"ref_27","unstructured":"European Medicine Agency (2025, June 18). EMA Confirms Recommendation for Non-Renewal of Authorisation of Duchenne Muscular Dystrophy Medicine Translarna. Available online: https:\/\/www.ema.europa.eu\/en\/news\/ema-confirms-recommendation-non-renewal-authorisation-duchenne-muscular-dystrophy-medicine-translarna."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1016\/j.ymthe.2025.04.038","article-title":"Clinical applications of exon-skipping antisense oligonucleotides in neuromuscular diseases","volume":"33","author":"Aguti","year":"2025","journal-title":"Mol Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s40259-024-00665-2","article-title":"Mechanisms of Action of the US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs","volume":"38","author":"Sang","year":"2024","journal-title":"BioDrugs"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1089\/nat.2018.0756","article-title":"A Sequel to the Eteplirsen Saga: Eteplirsen is Approved in the United States but Was Not Approved in Europe","volume":"29","author":"Goemans","year":"2019","journal-title":"Nucleic Acid Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s40265-016-0657-1","article-title":"Eteplirsen: First Global Approval","volume":"76","author":"Syed","year":"2016","journal-title":"Drugs"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2147\/DDDT.S97635","article-title":"Eteplirsen in the Treatment of Duchenne Muscular Dystrophy","volume":"11","author":"Lim","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/nat.2016.0657","article-title":"FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga","volume":"27","author":"Krieg","year":"2017","journal-title":"Nucleic Acid Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40265-020-01267-2","article-title":"Golodirsen: First Approval","volume":"80","author":"Heo","year":"2020","journal-title":"Drugs"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1358\/dot.2020.56.8.3159186","article-title":"Golodirsen for Duchenne Muscular Dystrophy","volume":"56","author":"Anwar","year":"2020","journal-title":"Drugs Today"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1089\/nat.2020.0845","article-title":"The 10th Oligonucleotide Therapy Approved: Golodirsen for Duchenne Muscular Dystrophy","volume":"30","author":"Corey","year":"2020","journal-title":"Nucleic Acid Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1089\/nat.2021.0043","article-title":"Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-Human, Multicenter, Two-Part, Open-Label, Phase 1\/2 Trial","volume":"32","author":"Servais","year":"2022","journal-title":"Nucleic Acid Ther."},{"key":"ref_38","first-page":"235","article-title":"Pharmacological Profile of Viltolarsen for the Treatment of Duchenne Muscular Dystrophy: A Japanese Experience","volume":"13","author":"Roshmi","year":"2021","journal-title":"Clin. Pharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1358\/dot.2019.55.10.3045038","article-title":"Viltolarsen for the Treatment of Duchenne Muscular Dystrophy","volume":"55","author":"Roshmi","year":"2019","journal-title":"Drugs Today"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"eaan0713","DOI":"10.1126\/scitranslmed.aan0713","article-title":"Systemic Administration of the Antisense Oligonucleotide NS-065\/NCNP-01 for Skipping of Exon 53 in Patients with Duchenne Muscular Dystrophy","volume":"10","author":"Komaki","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1002\/acn3.51235","article-title":"Viltolarsen in Japanese Duchenne Muscular Dystrophy Patients: A Phase 1\/2 Study","volume":"7","author":"Komaki","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s40265-021-01512-2","article-title":"Casimersen: First Approval","volume":"81","author":"Shirley","year":"2021","journal-title":"Drugs"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Assefa, M., Gepfert, A., Zaheer, M., Hum, J.M., and Skinner, B.W. (2024). Casimersen (AMONDYS 45\u2122): An Antisense Oligonucleotide for Duchenne Muscular Dystrophy. Biomedicines, 12.","DOI":"10.3390\/biomedicines12040912"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Chwalenia, K., Wood, M.J.A., and Roberts, T.C. (2025). Progress and prospects in antisense oligonucleotide-mediated exon skipping therapies for Duchenne muscular dystrophy. J. Muscle Res. Cell Motil., online ahead of print.","DOI":"10.1007\/s10974-024-09688-2"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Arechavala-Gomeza, V., L\u00f3pez-Mart\u00ednez, A., and Aartsma-Rus, A. (2025). Antisense RNA therapies for muscular dystrophies. J. Neuromuscul. Dis., online ahead of print.","DOI":"10.1177\/22143602251324858"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","article-title":"Systemic AAV Micro-Dystrophin Gene Therapy for Duchenne Muscular Dystrophy","volume":"26","author":"Duan","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1080\/14737175.2023.2249607","article-title":"Gene Therapy for Duchenne Muscular Dystrophy: An Update on the Latest Clinical Developments","volume":"23","author":"Tremblay","year":"2023","journal-title":"Expert Rev. Neurother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41434-024-00494-6","article-title":"AAV Gene Therapy for Duchenne Muscular Dystrophy: Lessons Learned from a Phase 3 Trial","volume":"31","author":"Baranello","year":"2024","journal-title":"Hum. Gene Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s40265-023-01929-x","article-title":"Delandistrogene Moxeparvovec: First Approval","volume":"83","author":"Hoy","year":"2023","journal-title":"Drugs"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/ana.26755","article-title":"Delandistrogene Moxeparvovec Gene Therapy in Ambulatory Patients (Aged \u22654 to <8 Years) with Duchenne Muscular Dystrophy: 1-Year Interim Results from Study SRP-9001-103 (ENDEAVOR)","volume":"94","author":"Zaidman","year":"2023","journal-title":"Ann. Neurol."},{"key":"ref_51","unstructured":"US Food and Drug Administration (2025, June 18). FDA Expands Approval of Gene Therapy for Patients with Duchenne Muscular Dystrophy, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-expands-approval-gene-therapy-patients-duchenne-muscular-dystrophy."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1080\/14712598.2024.2394477","article-title":"The FDA Approval of Delandistrogene Moxeparvovec-Rokl for Duchenne Muscular Dystrophy: A Critical Examination of the Evidence and Regulatory Process","volume":"24","author":"Bhattacharyya","year":"2024","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.cell.2020.03.023","article-title":"CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors","volume":"181","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1172\/JCI136873","article-title":"Correction of Muscular Dystrophies by CRISPR Gene Editing","volume":"130","author":"Chemello","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1126\/science.aau1549","article-title":"Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy","volume":"362","author":"Amoasii","year":"2018","journal-title":"Science"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41591-019-0738-2","article-title":"Somatic gene editing ameliorates skeletal and cardiac muscle failure in pig and human models of Duchenne muscular dystrophy","volume":"26","author":"Moretti","year":"2020","journal-title":"Nat. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.ymthe.2019.06.012","article-title":"AAV9 Edits Muscle Stem Cells in Normal and Dystrophic Adult Mice","volume":"27","author":"Nance","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.omtm.2020.09.016","article-title":"In Vivo Gene Editing of Muscle Stem Cells with Adeno-Associated Viral Vectors in a Mouse Model of Duchenne Muscular Dystrophy","volume":"19","author":"Kwon","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_59","first-page":"17","article-title":"Gene Editing for Duchenne Muscular Dystrophy: From Experimental Models to Emerging Therapies","volume":"15","author":"Haque","year":"2025","journal-title":"Degener. Neurol. Neuromuscul. Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1055\/s-0044-1791803","article-title":"The Role of CRISPR\/Cas9 in Revolutionizing Duchenne\u2019s Muscular Dystrophy Treatment: Opportunities and Obstacles","volume":"11","author":"Ali","year":"2024","journal-title":"Glob. Med. Genet."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Dhoke, N.R., Kim, H., Azzag, K., Crist, S.B., Kiley, J., and Perlingeiro, R.C.R. (2024). A Novel CRISPR-Cas9 Strategy to Target DYSTROPHIN Mutations Downstream of Exon 44 in Patient-Specific DMD iPSCs. Cells, 13.","DOI":"10.3390\/cells13110972"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1097\/MS9.0000000000002146","article-title":"Revolutionary Breakthrough: FDA Approves CASGEVY, the First CRISPR\/Cas9 Gene Therapy for Sickle Cell Disease","volume":"86","author":"Singh","year":"2024","journal-title":"Ann. Med. Surg."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1056\/NEJMoa2307798","article-title":"Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne\u2019s Muscular Dystrophy","volume":"389","author":"Lek","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jcp.25048","article-title":"Mechanisms and Consequences of Double-Strand DNA Break Formation in Chromatin","volume":"231","author":"Cannan","year":"2016","journal-title":"J. Cell Physiol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/nature16526","article-title":"High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects","volume":"529","author":"Kleinstiver","year":"2016","journal-title":"Nature"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nbt.3437","article-title":"Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9","volume":"34","author":"Doench","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Sandon\u00e0, M., Cavioli, G., Renzini, A., Cedola, A., Gigli, G., Coletti, D., McKinsey, T.A., Moresi, V., and Saccone, V. (2023). Histone Deacetylases: Molecular Mechanisms and Therapeutic Implications for Muscular Dystrophies. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24054306"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.molmed.2024.01.007","article-title":"HDAC Inhibitors as Pharmacological Treatment for Duchenne Muscular Dystrophy: A Discovery Journey From Bench to Patients","volume":"30","author":"Mozzetta","year":"2024","journal-title":"Trends Mol. Med."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Aartsma-Rus, A. (2025). Histone Deacetylase Inhibition with Givinostat: A Multi-Targeted Mode of Action with the Potential to Halt the Pathological Cascade of Duchenne Muscular Dystrophy. Front. Cell Dev. Biol., 12.","DOI":"10.3389\/fcell.2024.1514898"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2217\/epi.14.36","article-title":"Histone Deacetylase Inhibitors: A Potential Epigenetic Treatment for Duchenne Muscular Dystrophy","volume":"6","author":"Consalvi","year":"2014","journal-title":"Epigenomics"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2119\/molmed.2011.00049","article-title":"Histone Deacetylase Inhibitors in the Treatment of Muscular Dystrophies: Epigenetic Drugs for Genetic Diseases","volume":"17","author":"Consalvi","year":"2011","journal-title":"Mol. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/emmm.201202096","article-title":"Fibroadipogenic Progenitors Mediate the Ability of HDAC Inhibitors to Promote Regeneration in Dystrophic Muscles of Young, But Not Old Mdx Mice","volume":"5","author":"Mozzetta","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1101\/gad.234468.113","article-title":"HDAC-Regulated MyomiRs Control BAF60 Variant Exchange and Direct the Functional Phenotype of Fibro-Adipogenic Progenitors in Dystrophic Muscles","volume":"28","author":"Saccone","year":"2014","journal-title":"Genes Dev."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e50863","DOI":"10.15252\/embr.202050863","article-title":"HDAC Inhibitors Tune miRNAs in Extracellular Vesicles of Dystrophic Muscle-Resident Mesenchymal Cells","volume":"21","author":"Consalvi","year":"2020","journal-title":"EMBO Rep."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e54721","DOI":"10.15252\/embr.202254721","article-title":"Determinants of Epigenetic Resistance to HDAC Inhibitors in Dystrophic Fibro-Adipogenic Progenitors","volume":"23","author":"Consalvi","year":"2022","journal-title":"EMBO Rep."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2119\/molmed.2013.00011","article-title":"Preclinical Studies in the mdx Mouse Model of Duchenne Muscular Dystrophy with the Histone Deacetylase Inhibitor Givinostat","volume":"19","author":"Consalvi","year":"2013","journal-title":"Mol. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.nmd.2016.07.002","article-title":"Histological Effects of Givinostat in Boys with Duchenne Muscular Dystrophy","volume":"26","author":"Bettica","year":"2016","journal-title":"Neuromuscul. Disord."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S1474-4422(24)00036-X","article-title":"Safety and Efficacy of Givinostat in Boys with Duchenne Muscular Dystrophy (EPIDYS): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"23","author":"Mercuri","year":"2024","journal-title":"Lancet Neurol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40265-024-02052-1","article-title":"Givinostat: First Approval","volume":"84","author":"Lamb","year":"2024","journal-title":"Drugs"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"16456","DOI":"10.1073\/pnas.1910456117","article-title":"Premature Termination Codons in the DMD Gene Cause Reduced Local mRNA Synthesis","volume":"117","author":"Hiller","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Mercuri, E., Pane, M., Cicala, G., Brogna, C., and Ciafaloni, E. (2023). Detecting Early Signs in Duchenne Muscular Dystrophy: Comprehensive Review and Diagnostic Implications. Front. Pediatr., 11.","DOI":"10.3389\/fped.2023.1276144"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/mus.26803","article-title":"Neurodevelopmental, behavioral, and emotional symptoms common in Duchenne muscular dystrophy","volume":"61","author":"Darmahkasih","year":"2020","journal-title":"Muscle Nerve"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1136\/jmedgenet-2015-103387","article-title":"The Importance of Genetic Diagnosis for Duchenne Muscular Dystrophy","volume":"53","author":"Ginjaar","year":"2016","journal-title":"J. Med. Genet."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clinbiochem.2021.09.010","article-title":"Creatine Kinase Test Diagnostic Accuracy in Neonatal Screening for Duchenne Muscular Dystrophy: A Systematic Review","volume":"98","author":"Nakata","year":"2021","journal-title":"Clin. Biochem."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1126\/science.aam9321","article-title":"Nucleic acid detection with CRISPR-Cas13a\/C2c2","volume":"356","author":"Gootenberg","year":"2017","journal-title":"Science"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.cell.2016.04.059","article-title":"Rapid, Low-Cost Detection of Zika Virus Using Programmable Biomolecular Components","volume":"165","author":"Pardee","year":"2016","journal-title":"Cell"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41551-019-0371-x","article-title":"Detection of Unamplified Target Genes via CRISPR-Cas9 Immobilized on a Graphene Field-Effect Transistor","volume":"3","author":"Hajian","year":"2019","journal-title":"Nat. Biomed. Eng."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.nmd.2010.04.005","article-title":"Best practice guidelines on molecular diagnostics in Duchenne\/Becker muscular dystrophies","volume":"20","author":"Abbs","year":"2010","journal-title":"Neuromuscul. Disord."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/uog.15986","article-title":"Total pregnancy loss after chorionic villus sampling and amniocentesis: A cohort study","volume":"49","author":"Bakker","year":"2017","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/GCO.0000000000000347","article-title":"Noninvasive Prenatal Diagnosis for Single Gene Disorders","volume":"29","author":"Allen","year":"2017","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"20458","DOI":"10.1073\/pnas.0810641105","article-title":"Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic","volume":"105","author":"Chiu","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/pd.4781","article-title":"Non-Invasive Prenatal Diagnosis of Duchenne and Becker Muscular Dystrophies by Relative Haplotype Dosage","volume":"36","author":"Parks","year":"2016","journal-title":"Prenat. Diagn."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Zaninovi\u0107, L., Ba\u0161kovi\u0107, M., Je\u017eek, D., and Bojanac, A.K. (2023). Accuracy of Non-Invasive Prenatal Testing for Duchenne Muscular Dystrophy in Families at Risk: A Systematic Review. Diagnostics, 13.","DOI":"10.3390\/diagnostics13020183"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"329","DOI":"10.4103\/jhrs.jhrs_148_21","article-title":"Evolution and Utility of Preimplantation Genetic Testing for Monogenic Disorders in Assisted Reproduction\u2014A Narrative Review","volume":"14","author":"Parikh","year":"2021","journal-title":"J. Hum. Reprod. Sci."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1002\/pd.1317","article-title":"Preimplantation genetic diagnosis (PGD) for Duchenne muscular dystrophy (DMD) by triplex-nested PCR","volume":"25","author":"Malcov","year":"2005","journal-title":"Prenat. Diagn."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/molehr\/gal039","article-title":"PGD for dystrophin gene deletions using fluorescence in situ hybridization","volume":"12","author":"Malmgren","year":"2006","journal-title":"Mol. Hum. Reprod."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.fertnstert.2007.11.044","article-title":"Preimplantation genetic diagnosis for Duchenne muscular dystrophy by multiple displacement amplification","volume":"91","author":"Ren","year":"2009","journal-title":"Fertil. Steril."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1016\/j.rbmo.2019.04.115","article-title":"Successful strategy of comprehensive pre-implantation genetic testing for Duchenne muscular dystrophy and chromosome balance using karyomapping and fluorescent PCR","volume":"39","author":"Mongkolchaipak","year":"2019","journal-title":"Reprod. Biomed. Online"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/14\/6742\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:09:44Z","timestamp":1760033384000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/14\/6742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":98,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["ijms26146742"],"URL":"https:\/\/doi.org\/10.3390\/ijms26146742","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,14]]}}}